Interstitial high-dose rate brachytherapy as boost for anal canal cancer by Alexander Tuan Falk et al.
Falk et al. Radiation Oncology 2014, 9:240
http://www.ro-journal.com/content/9/1/240RESEARCH Open AccessInterstitial high-dose rate brachytherapy as boost
for anal canal cancer
Alexander Tuan Falk1,2, Audrey Claren1,2, Karen Benezery1, Eric François3, Mathieu Gautier1, Jean-Pierre Gerard1
and Jean-Michel Hannoun-Levi1,2*Abstract
Aim: To assess clinical outcomes of patients treated with a high-dose rate brachytherapy boost for anal canal
cancer (ACC).
Methods: From August 2005 to February 2013, 28 patients presenting an ACC treated by split-course external beam
radiotherapy (EBRT) and HDR brachytherapy with or without chemotherapy in a French regional cancer center in
Nice were retrospectively analyzed.
Results: Median age was 60.6 years [34 – 83], 25 patients presented a squamous cell carcinoma and 3 an
adenocarcinoma; 21 received chemotherapy. Median dose of EBRT was 45 Gy [43.2 – 52]. Median dose of HDR
brachytherapy was 12 Gy [10 - 15] with a median duration of 2 days. Median overall treatment time was 63 days
and median delay between EBRT and brachytherapy was 20 days. Two-year local relapse free, metastatic free,
disease free and overall survivals were 83%, 81.9%, 71.8% and 87.7% respectively. Acute toxicities were frequent but
not severe with mostly grade 1 toxicities: 37% of genito-urinary, 40.7% of gastro-intestinal and 3.7% of cutaneous
toxicities. Late toxicities were mainly G1 (43.1%) and G2 (22%). Two-year colostomy-free survival was 75.1%, one
patient had a definitive sphincter amputation.
Conclusion: High-dose rate brachytherapy for anal canal carcinoma as boost represents a feasible technique
compared to low or pulsed-dose rate brachytherapy. This technique remains an excellent approach to precisely
boost the tumor in reducing the overall treatment time.
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Anal canal carcinoma (ACC) is a rare disease with an
incidence rate of less than 10 cases per 1 000 000
habitants in Europe [1], which has been considered as a
life deteriorating even when cured because of sphincter
amputation caused by historical surgical treatment. The
impact on quality of life has pushed clinicians to consider
new treatment ways. Conservative treatments for sphinc-
ter preservation in ACC have become a standard, even for
large tumors. Gold standard treatment consists of con-
comitant radiotherapy and chemotherapy with Mitomycin
and 5-Fluorouracil [2-4]. Clinical target volume consists
of the gross tumor volume and the loco-regional lymph* Correspondence: jean-michel.hannoun-levi@nice.unicancer.fr
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unless otherwise stated.nodes with a dose of 45 to 50 Gy with a sequential boost
delivered by either external beam radiation therapy
(EBRT) or by interstitial brachytherapy (BCT) [5,6]. All
attempts to find a better standard of chemotherapy have
failed [7]. However, recent development of radiotherapy
technique have permitted better care and new treatment
strategies for ACC [8,7].
There is no agreement for the boost technique. Stand-
ard brachytherapy technique remains based on LDR or
PDR [9,10]. However as proposed for numerous tumors
(prostate [11] and cervical cancer [12]) HDR brachytherapy
appears to be more and more used mainly because of radio-
protection considerations, dose distribution optimization
and shorter treatment time [13]. Currently, there is few
available data focusing on high-dose rate brachytherapy for
ACC. This study was aimed to assess clinical outcomes of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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This study retrospectively analyzed the clinical outcome
of patients with histology-proven ACC treated by split-
course radiotherapy and HDR brachytherapy with or with-
out chemotherapy in the Centre Antoine Lacassagne, a
regional cancer center in Nice, France. The study design
and analysis was approved by the local institutional ethic
comity of Antoine Lacassagne Cancer Center.
From August 2005 to February 2013, 28 patients were
retrospectively analyzed. All the patients had a clinical
exam and follow-up done by trained physicians of the
center. According to local rules, patients underwent a
digital rectal examination with a dated schema, anuscopy,
computed-tomography scan, magnetic resonance imaging
and endorectal ultrasonography. PET-scan was performed
at the discretion of the physician. Tumors were staged
using the UICC-cTNM classification (2002 – 6th edition).
All the patients presenting with a tumor involving no
more than 2/3 of the anal canal circumference were eli-
gible for brachytherapy boost. Due to a high risk of necro-
sis/stenosis, circumferential tumor was considered as a
definitive exclusion criteria for brachytherapy.Figure 1 Dose distribution analysis on the post-implant CT-scan.Treatment features
Concomitant radio-chemotherapy
The first part of the treatment consisted of EBRT with
or without concurrent chemotherapy. Radiotherapy de-
livered a total dose of 45 to 46 Gy in 25 or 23 fractions
based on a 3-dimensional conformational technique with
or without intensity modulated. The dose was delivered to
the ICRU point (International Commission on Radiation
Units Measurements) using high-energy X-photons (>10
MV). The clinical target volume (CTV) was the whole
pelvis. The planning target volume (PTV) was defined as
a 1 cm margin around the CTV in all directions. Inclusion
of the inguinal nodes was set at the discretion of the
radiation oncologist.
Patients who received concomitant chemotherapy were
administrated Mitomycin C - 5FU or Cisplatin - 5FU.
HDR brachytherapy boost
Brachytherapy boost was performed unless patients could
not undergo general anesthesia or presented with a tumor
invasion >2/3 of the circumference. HDR brachytherapy
was performed after the patient recovered from perineal
dermatitis. After a 2 day fiber free diet and enema the day
before and one-hour before procedure. A digital exam and
anuscopy were performed under general anesthesia in order
to evaluate the tumor response after radio-chemotherapy.
Table 1 Patient, tumor and treatment features
Items N/Median Interval/%
Age (years) 60 [34 – 83]
Sex ratio (F/M) 3















Inguinal irradiation 20 71.4
Total dose (Gy) 45 [43.2 – 52]
HDR BT
d/f (Gy) 4 [3 – 5]
# of fractions 3 [2 – 6]
Total dose (Gy) 12 [10 – 15]
# of needles 4 [4 – 7]
TI EBRT/BT (days) 20 [4 – 63]
OTT (days) 63 [38 – 74]
SCC: squamous cell carcinoma; ADC: adenocarcinoma; EBRT: external beam
radiation therapy; HDR BT: high-dose rate brachytherapy; d/f: dose per fraction;
TI EBRT/BT: time interval between external beam radiation therapy and
brachytherapy; OTT: overall treatment time.
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then, needles (Sharp Needles™; Nucletron, an Elekta com-
pany, Elekta AB, Stockholm, Sweden) were implanted
under general anesthesia according to the pre-treatment
target volume (based on the initial schema) respecting
a minimal distance of 4 to 5 mm from the needles to
the anal canal mucosa. We used a dedicated circular
perineal template punched by a total of 10 holes (every
12 mm) allowing to keep the implanted needles equi-
distant and parallel. A plastic tube (20 mm in exter-
nal diameter) was placed into the anal canal and fixed
to the perineal template which was finally sutured to
the skin. After recovery, post-implant planning CT-
scan was performed in the radiation oncology de-
partment for treatment planning purposes. CTV was
delineated (anal canal initial tumor) using a 10 mm
in diameter pearl.
Regarding the prescribed dose, our standard protocol
was based on the result of the digital rectal exam per-
formed under general anesthesia before the implant. In
case of complete clinical response, a total dose of 12 Gy in
3 fractions over 24 hours (EQD2αβ3 = 17 Gy/EQD2αβ10 =
15 Gy) was prescribed (1 fraction delivered the day of
implant and 2 fractions at least 6 hours apart the day
after). In case of partial clinical response, a total dose of
15 Gy in 3 fractions over 24 hours (EQD2αβ3 = 24 Gy/
EQD2αβ10 = 19 Gy) was prescribed. Dose-volume adapta-
tion was manually achieved using graphical optimization
(OncentraBrachy, Nucletron, an Elekta company, Elekta
AB, Stockholm, Sweden) by dwell location and time
variation (Figure 1). During the treatment, the patient was
treated in his bed and hospitalized in a non-shielded
room. After the last irradiation session, the needles were
removed and the patient left the hospital the day after.
Regarding dosimetric results, D90 (dose delivered to
90% of the CTV) and D100 were reported as well as V100
(volume receiving 100% of the prescribed dose), V150
and V200. DHI (Dose Homogeneity Index: [V100-V150]/
V100) was also calculated.
Follow-up and evaluation
Patients were followed-up one month after HDR brachy-
therapy then, every semester with radiation oncologist
and gastro-enterologist alternatively by clinical examin-
ation, endorectal ultrasonography and MRI if necessary.
Local (LRFS) and metastatic (MRFS) relapse-free survivals
as well as disease free (DFS), overall (OS) and colostomy-
free (CFS) survivals were analyzed. Early and late toxicities
rates were graded using the NCI-Common criteria version
4.0 [14].
Statistical analysis
All the data was analyzed using SPSS 20.0 (IBM Corporation).
Overall survival was defined as the delay between date ofdiagnostic and the date of death. Relapse was defined
as the delay between the date of diagnostic and the date
of relapse. These statistics were estimated and repre-
sented graphically using Kaplan-Meier method. Patients
were censored at the moment of their death or their last
follow-up.
Results
Twenty-eight patients (pts) were analyzed in this study;
patient characteristics are reported in Table 1. Median
follow-up was 27.5 [4–98 months] and median age was
60.6 years [34–83 years]. Median initial tumor size was
3 cm [1–6 cm] and, using cTNM classification, the large
majority of the patients were classified as T1/2 (90%).
Histologic subtypes were as follow: 25 pts presented a squa-
mous cell carcinoma and 3 pts an adenocarcinoma. Two
patients were HIV positive. Twenty-one patients (71.4%)
Table 2 Dosimetric data
Data Median Interval
CTV (cc) 22.3 [8.6 - 46.7]
D90% 108 [32 – 117]
EQD2 αβ10 (Gy) 15.1 [5.5 – 20.6]
EQD2 αβ3 (Gy) 18.1 [6.9 – 26.4]
D100% 77 [20 – 95]
EQD2 αβ10 (Gy) 10.9 [3.4 – 14.4]
EQD2 αβ3 (Gy) 13.3 [4.3 – 18.5]
V100
% 96 [58 – 100]
cc 18 [8.1 – 45.8]
V150
% 37 [26 – 57]
cc 7.2 [2.5 – 26.6]
V200
% 19 [10 – 26]
cc 3.4 [1.2 – 11.7]
DHI 0.58 [0.42 – 0.99]
CTV: Clinical target volume; D90: dose delivered to 90% of the CTV; EQD2
αβ10: equivalent dose at 2 Gy per fraction for αβ10 (tumor); EQD2 αβ3:
equivalent dose at 2 Gy per fraction for αβ3 (normal tissues); V100: volume
which received 100% of the prescribed dose; V150: volume which received
150% of the prescribed dose; V200: volume which received 200% of the
prescribed dose; DHI: dose homogeneity index.
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pts received 5FU/Cisplatin). Patients received a median
dose of EBRT of 45 Gy [43.2–52 Gy] over a median EBRT
treatment time of 37 days [32–52 days]. Median dose for
HDR brachytherapy was 12 Gy [10–15 Gy]. Median dur-
ation of brachytherapy was 2 days [2,3]. Median overallFigures 2 Kaplan-Meier curves for local disease free survival (A) and mtreatment time was 63 days [38–74 days] and median
delay between EBRT and HDR brachytherapy was 20 days
[4–63 days]. Dosimetric data are reported in Table 2.
Briefly, median CTV was 22.3 cc [8.6 - 46.7 cc], V100 was
96% [58 – 100%] and median DHI was 0.55 [42 – 99].
In terms of clinical outcomes, 2-years LRFS and MRFS
rates were 83% [Standard Error (SE) 7.8%] and 81.9%
[SE 9.5%] respectively (Figure 2A and 2B).Two-year DFS
and OS rates were 71.8% [SE 10.7%] and 87.7% [SE 8.2%]
(Figure 3A and 3B) respectively.
Acute toxicities following HDB (<2 months) were fre-
quent but not severe. Indeed, genito-urinary (GU), gastro-
intestinal (GI) and cutaneous toxicities were always grade
1 (G1) and occurred in 37%, 40.7% and 3.7% respectively.
Late toxicities were mainly G1 (43.1%) and G2 (22%). GI
complications were: rectal bleeding (16.5%), perineal pain
(13.2%), telangiectasia (13.2%), diarrhea (9.9%), rectal
mucus (9.9%), constipation (3.3%), abdominal pain (3.3%)
and rectal pain (3.3%). GU complications were: frequent
urination (13.2%), incontinence (6.6%), hematuria (3.3%),
urgency (3.3%). Two women (7.1%) presented G3 late
complications: the first (HIV-positive) with grade 2 rectal
bleeding and grade 3 anal ulceration, with complete recov-
ery after 5 years; the second with a grade 3 anal necrosis
managed with colostomy. Two-year CFS was 75.1% [SE
11.6%] (Figure 4). Among the four patients (14.3%) who
underwent a colostomy, one was associated with a defini-
tive sphincter amputation.
Discussion
Brachytherapy plays a key role in the management of
ACC as boost after a first course of EBRT with or without
concomitant chemotherapy [5]. From now, brachytherapy
for ACC used mainly LDR or PDR. However, due to theetastatic free survival (B).
Figures 3 Kaplan-Meier curves for disease free survival (A) and overall survival (B).
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radioprotection and cost-effective considerations, HDR
brachytherapy gains, step by step, in respectability. While
this technique represents a standard treatment for cervical
[12] and prostate cancers [11], there is very few available
data concerning ACC.
Optimization of dose distribution used with PDR/HDR
brachytherapy represents in general a real advantage com-
pare to LDR brachytherapy. However, specifically for ACC
brachytherapy, because of the very proximal situation
of the CTV in regards to the perineal template used
(optimal needle guidance), the impact of dose optimization is
maybe less important although adequate coverage ofFigure 4 Colostomy-free survival.the anal mucosa (avoiding overdose area) appears more
feasible. Classical dosimetric parameters used for HDR
brachytherapy (CTV, D90, D10, V100, V150 and V200)
can be used for ACC. Kapoor et al. [15] recently reported
the results of 16 patients treated by radio-chemotherapy
and HDR brachytherapy and presented dosimetric data
with a mean DHI of 0.83 [0.55–0.98]. In our study, we
reported a median DHI of 0.58.
In terms of clinical outcomes, specifically regarding
OS, CFS and toxicity ≥G3, it seems that our results are
comparable to previous ACC brachytherapy series using
LDR, PDR or HDR (Table 3). For LCR, our series re-
ported a rate of 83% with a 27.5 median FU. This result
Table 3 Comparative overview of the literature focusing on brachytherapy boost for anal canal carcinoma according to the brachytherapy dose-rate
Authors (Year) # pts* Median FU (months) Dose Rate Median BT dose (Gy) LR (%) OS (%) Colostomy Late toxicity ≥ G3 [%]
LRR (%) LCR (%) CR % CFS %
Peiffert et al. (1997) [16] 101/118 72 LDR 21.5 N/A 60 (5 y) 9 - 13.5
Papillon et al. (1989) [17] 221 > 36 LDR 20 to 30 N/A 69.2 (3 y) 2.7 - N/A
Wagner et al. (1994) [18] 96 35.5 to 51.7** LDR 20.2** 16.6 - 64 (5 y) N/A 9.25
Gerard et al. (1999) [19] 19 N/A PDR 10 to 25 5,2 - 100 (1 y) 0 - 0
Bruna et al. (2006) [20] 71 28.5 PDR 17.8** N/A 90 (2y) - 89 (2 y) N/A
Roed et al. (1996) [10] 17 11.3 PDR 28.85 23.5 - N/A 47 - N/A
Kapp et al. (2001) [21] 39 31 HDR 6 to 12*** 81 (3 y) 80 (3 y DSS) - 78 (3 y) 7.6
76 (5 y) 76 (5 y DSS) 73 (5 y)
Vordermark et al. (2001) [5] 20 52.8** HDR 5 to 12 5 - 84 (5 y) - 68.9 (5 y) N/A
Doniec et al. (2006) [23] 50 34 HDR 8 to 12 N/A 74 (5 y) 4 - N/A
Oehler-Jänne et al. (2007) [24] 34 60** HDR 14 10.3 (5y) - 66 (10 y) 15 - N/A
Saarilahti et al. (2008) [25] 29/59 51 HDR 12 N/A N/A N/A N/A
Kapoor et al. (2013) [15] 16 41 HDR 18 (6f) - 87.5 (2 y) N/A N/A 0
21 (7f) N/A
Falk et al. (2014) 28 27.5 HDR 12 (3f) - 83 (2 y) 87.7 - 75.1 (2 y) 7.1
*If ratio, number of patients treated by brachytherapy boost/total number of patients treated.
**Mean.
***6 Gy during the EBT period and 6 Gy after EBT in case of partial response.
# pts: number of patients; FU: follow-up; BT: brachytherapy; LR: local recurrence; LRR: local recurrence rate; LCR: local control rate; OS: overall survival; CR: colostomy rate; CFS : colostomy free survival; LDR: low-dose rate
















Table 4 Overview of the literature focusing on external radiotherapy for anal canal carcinoma




LR OS (%) Colostomy Late
toxicity ≥
G3 [%]Initial Boost LRR (%) LCR (%) CR % CFS %
Northover et al. (2010) [5] 2DRT 290 157 45 N/A 57.1 (5 y) 33.7 (5 y) 53 (5 y) 36.8 (5 y) N/A
Northover et al. (2010) [5] 2DRT + CT 295 157 45 N/A 32.3 (5 y) 46.6 (5 y) 58.1 (5 y) 46.9 (5 y) N/A
Ajani et al. (2008) [23] 2DRT MMC-arm 324 30 45 10-14 25 (5 y) 84% (5 y) 10% (5y) 11%
Kachnic et al. (2013) [24] IMRT 43 24 42* 50.4* 95% (2 y) 94% (2 y) 90% (2 y) 7%
50.4** 54**
*For T1-T2 : 42 Gy with 50.4 Gy integrated boost on the tumor volume.
**For T3-T4 : 50.4 Gy with 54 Gy integrated boost on the tumor volume.
EBT: external beam radiation therapy; # pts: number of patients; FU: follow-up; LR: local recurrence; LRR: local recurrence rate; LCR: local control rate; OS: overall
survival; CR: colostomy rate; CFS : colostomy free survival; NA: non-applicable; DSS: disease specific survival; 2DRT: 2 dimension radiation therapy; CT: chemotherapy;
MMC: Mitomycin-C; IMRT: intensity modulated radiation therapy; N/A: not applicable.
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HDR studies [16-19,15]. We reported a 2-year OS rate
of 87.7%. A historical clinical study published by Papillon
et al. [9] focusing on LDR brachytherapy showed a 69.2%
OS rate at 3 years. More recent PDR studies from Gerard
et al. [20] and Bruna et al. [21] found respectively an
OS rate of 100% at 1 year and 90% at 2 years. Lòpez
Guerrera et al. [22] presented a mixed study of LDR and
PDR brachytherapy with a 2-year OS rate of 87%. These
results are similar to those observed with external radio-
therapy (Table 4).
Our patients presented frequent grade 1–2 toxicities
but grade 3 toxicities only occurred for 7.1% of patients.
Severe toxicities (≥ G3) were reported in 0 to 13.5% of
patients in LDR/PDR studies [9,25,26,10,20,27] and in 0
to 7.6% in HDR studies [28,29]. Only 2 patients pre-
sented severe grade 3 toxicities, one of them with an
HIV-positive status which could account for higher tox-
icities [30]. Compared to our results, Kapoor et al. [15]
reported no grade 3 toxicities with a similar LCR. This
observation could be explained by the difference in
terms of DHI with a less homogeneous implant in our
cohort. On another hands, the total number of HDR
brachytherapy fractions ranged between 6 and 7 in the
Kapoor et al. study while in our cohort, the patients
were treated with only 3 fractions (potential reduction of
the hospitalization time). Nevertheless, our CFS rate (75.1%)
remains comparable to other published data on LDR, PDR
and HDR brachytherapy [16,28].
Due to its design, we weren’t able to access quality of
life. To our knowledge, there is no comparative assessing
quality of life for brachytherapy boost. External radio
chemotherapy seems to be associated with good quality
of life with 77% patients being satisfied of their body
[31]. Recent international guidelines have encouraged
the study and evaluation of sexual, urinary and sphincter
dysfunction as the data are scarce [32].
This study presented limitations. Data collection was
retrospective and monocentric. Median follow-up wasshort (27.5 months). We didn’t directly compare our
data to low or pulsed-dose rate brachytherapy or EBRT
boost.
HDR brachytherapy has advantages compared to low or
PDR brachytherapy. It permits less radiation exposure for
the medical staff and could provide better dose-distribution
compared to LDR brachytherapy. Patients can be hospital-
ized in a non-shielded room allowing visits of the family
(forbidden in case of LDR or PDR brachytherapy) with a
potential improvement of psychological experience. Fur-
thermore, with only one after-loader HDR machine, is
it possible to treat many patients per day while for LDR
or PDR, the number of treated patients per day will be
strongly correlated to the number of shielded-rooms
(potential cost-effective impact). To our knowledge, there
are no prospective studies evaluating HDR brachytherapy
for anal canal cancer boost after sequential EBRT. Further
data needs to be collected and maybe even compared to
LDR/PDR brachytherapy.
Conclusion
High-dose rate for anal canal carcinoma as boost repre-
sents a feasible technique compared to low or pulsed-dose
rate brachytherapy. This technique remains an excellent
approach to precisely boost the tumor in reducing the
overall treatment time while high-dose rate is more and
more used in the frame of brachytherapy. Currently
simultaneous-integrated boost (SIB) in case of intensity-
modulated EBRT represents a challenging therapeutic
option which could be compared to HDR brachytherapy
for ACC boost.
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